1
|
Abstract
Fournier's gangrene is a rapidly progressing necrotizing fasciitis restricted to the perineal and genital regions. Although rare, it is an acute life-threatening disease, requiring rapid radical surgical debridement and antibiotic treatment, resulting in large soft tissue defects. Various reconstructive methods for defect coverage are applied to satisfactorily reconstitute functionality and esthetics.
Collapse
Affiliation(s)
- E Comploj
- Abteilung für Urologie und Kinderurologie, Zentralkrankenhaus Bozen, Lorenz Böhler Straße 5, 39100, Bozen, Italien.
| | - A Pycha
- Abteilung für Urologie und Kinderurologie, Zentralkrankenhaus Bozen, Lorenz Böhler Straße 5, 39100, Bozen, Italien.,Sigmund Freud Medical School Wien, Wien, Österreich
| |
Collapse
|
2
|
Comploj E, Cassar W, Trenti E, Palermo S, Reinstadler P, Ladurner C, Dechet C, Pycha A. [Henoch-Schönlein purpura resulting in an obstructive bladder mass]. Aktuelle Urol 2013; 44:462-3. [PMID: 23824929 DOI: 10.1055/s-0033-1348244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Henoch-Schönlein purpura (HSP) is the most common form of an immunological systemic vasculitis of childhood. The classic clinical symptoms include purpuric rash, abdominal pain, arthralgias, and haematuria, but the spectrum of HSP may vary to very rare forms. This article reports on an 8-year-old girl with a Henoch-Schönlein purpura (HSP) which resulted in an obstructive bladder mass and subsequent urinary retention. This is the first case reported in the literature, describing such a course.
Collapse
Affiliation(s)
- E. Comploj
- Abteilung für Urologie, Zentralkrankenhaus Bozen, Bozen, Italien
| | - W. Cassar
- Abteilung für Pädiatrie, Zentralkrankenhaus Bozen, Bozen, Italien
| | - E. Trenti
- Abteilung für Urologie, Zentralkrankenhaus Bozen, Bozen, Italien
| | - S. Palermo
- Abteilung für Urologie, Zentralkrankenhaus Bozen, Bozen, Italien
| | - P. Reinstadler
- Abteilung für Pädiatrie, Zentralkrankenhaus Bozen, Bozen, Italien
| | - C. Ladurner
- Abteilung für Urologie, Zentralkrankenhaus Bozen, Bozen, Italien
| | - C. Dechet
- Abteilung für Urologie, Zentralkrankenhaus Bozen, Bozen, Italien
| | - A. Pycha
- Abteilung für Urologie, Zentralkrankenhaus Bozen, Bozen, Italien
| |
Collapse
|
3
|
Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, Shariat SF. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013; 109:1460-6. [PMID: 23982601 PMCID: PMC3776972 DOI: 10.1038/bjc.2013.372] [Citation(s) in RCA: 168] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2013] [Revised: 06/13/2013] [Accepted: 06/22/2013] [Indexed: 11/24/2022] Open
Abstract
Background: The European Organization for Research and Treatment of Cancer (EORTC) risk tables and the Spanish Urological Club for Oncological Treatment (CUETO) scoring model are the two best-established predictive tools to help decision making for patients with non-muscle-invasive bladder cancer (NMIBC). The aim of the current study was to assess the performance of these predictive tools in a large multicentre cohort of NMIBC patients. Methods: We performed a retrospective analysis of 4689 patients with NMIBC. To evaluate the discrimination of the models, we created Cox proportional hazard regression models for time to disease recurrence and progression. We incorporated the patients calculated risk score as a predictor into both of these models and then calculated their discrimination (concordance indexes). We compared the concordance index of our models with the concordance index reported for the models. Results: With a median follow-up of 57 months, 2110 patients experienced disease recurrence and 591 patients experienced disease progression. Both tools exhibited a poor discrimination for disease recurrence and progression (0.597 and 0.662, and 0.523 and 0.616, respectively, for the EORTC and CUETO models). The EORTC tables overestimated the risk of disease recurrence and progression in high-risk patients. The discrimination of the EORTC tables was even lower in the subgroup of patients treated with BCG (0.554 and 0.576 for disease recurrence and progression, respectively). Conversely, the discrimination of the CUETO model increased in BCG-treated patients (0.597 and 0.645 for disease recurrence and progression, respectively). However, both models overestimated the risk of disease progression in high-risk patients. Conclusion: The EORTC risk tables and the CUETO scoring system exhibit a poor discrimination for both disease recurrence and progression in NMIBC patients. These models overestimated the risk of disease recurrence and progression in high-risk patients. These overestimations remained in BCG-treated patients, especially for the EORTC tables. These results underline the need for improving our current predictive tools. However, our study is limited by its retrospective and multi-institutional design.
Collapse
Affiliation(s)
- E Xylinas
- 1] Department of Urology, Weill Cornell Medical College, New York, NY, USA [2] Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Martini T, Mayr R, Lodde M, Seitz C, Trenti E, Comploj E, Palermo S, Pycha A, Mian C, Zywica M, Weidner W, Lüdecke G. Validation of RiskCheck Bladder Cancer ©, version 5.0 for risk-adapted screening of bladder cancer. Urol Int 2013; 91:175-81. [PMID: 23860006 DOI: 10.1159/000351036] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2013] [Accepted: 04/01/2013] [Indexed: 11/19/2022]
Abstract
INTRODUCTION The aim of the study was to assess the strength of the online tool RiskCheck Bladder Cancer©, version 5.0 (RCBC) for early detection of bladder cancer (BC). MATERIALS AND METHODS RCBC was evaluated retrospectively based on the data of 241 patients, of which 141 were suffering from BC. Statistical analysis was performed by descriptive statistics, nonparametric group comparison, classification tree analysis and ROC analysis. RESULTS ROC analysis of the risk classification showed a sensitivity of 71.6%, a specificity of 56.5%, a positive predictive value of 67.8%, a negative predictive value of 52% and an accuracy of 63.5%. BC risk factors ranked by importance are time of smoking (p < 0.0001), gender (within the nonsmoking group: p < 0.009), occupational toxin exposure (within the group <35 years of smoking: p < 0.048) and amount of consumed cigarettes resulting in a 95% association with BC (within the group >35 years of smoking: p < 0.0001). CONCLUSIONS The high predictive power of RCBC for the identification of asymptomatic patients living under risk could be demonstrated.
Collapse
Affiliation(s)
- T Martini
- Department of Urology, General Hospital of Bolzano, Bolzano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Klatte T, Zigeuner R, Rouprêt M, Babjuk M, Capitanio U, Cha E, Colin P, Comploj E, Dalpiaz O, Fritsche HM, Herrmann T, Hora M, Hübner W, Merseburger A, Montorsi F, Nison L, Novara G, Roscigno M, Shariat S, Remzi M. 575 Segmental ureterectomy versus radical nephroureterectomy for urothelial cancer of the ureter: A matched-pair analysis. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/s1569-9056(13)61058-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Martini T, Madersbacher S, Lodde M, Comploj E, Trenti E, Palermo S, Berger I, Pycha A, Mayr R. UP-01.042 A Retrospective Evaluation of Radical Cystectomy Versus Bladder Preservation Therapy in Patients 80 Years Old and Older with Muscle-Invasive Bladder Cancer. Urology 2011. [DOI: 10.1016/j.urology.2011.07.594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
7
|
Mayr R, Martini T, Lodde M, May M, Pycha A, Comploj E, Otto W, Denzinger S, Burger M, Fritsche H. MP-04.08 Predictive Capacity of Four Comorbidity Indices Estimating Perioperative Mortality after Radical Cystectomy for Urothelial Carcinoma of the Bladder. Urology 2011. [DOI: 10.1016/j.urology.2011.07.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Caffo O, Sava T, Comploj E, Zustovich Z, Segati R, Fariello A, Perin A, Sacco C, Caldara A, Galligioni E. IMPACT OF DOCETAXEL (D) – BASED CHEMOTHERAPY ON QUALITY OF LIFE (QOL) OF PATIENTS (PTS) WITH HORMONE- REFRACTORY PROSTATE CANCER (HRPC): RESULTS FROM A RANDOMISED PHASE II TRIAL WITH D ± ESTRAMUSTINE (E). ACTA ACUST UNITED AC 2008. [DOI: 10.1016/s1569-9056(08)60637-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Caffo O, Sava T, Comploj E, Giampaolo M, Zustovich F, Segati R, Sacco C, Perin A, Pappagallo G, Valduga F. Docetaxel (D) and estramustine (E) as first-line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC): Final results of a multicentric phase II randomized trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15552] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15552 Background: Preclinical data showed a synergism between E and D and several studies supported an advantage in associating E and D. Nevertheless, D is considered a standard treatment for HRPC pts and the role of D+E combination remains controversial. Purpose of this study was to evaluate the activity, in terms of PSA decline (PSA↓), the safety and quality of life (QoL) of D±E in HRPC pts. Methods: Eligibility criteria included: HRPC diagnosis, hormone-refractory advanced disease (PSA progression after at least two hormonal therapy), ECOG PS < 2, adequate renal, hepatic and hematological functions, no prior chemotherapy. Pts were randomized to D 70 mg/m2 IV d1 q3w (arm A) or D 70 mg/m2 IV d1 q3w + E 280 mg/TID PO starting 1 day prior to D, for 5 consecutive days (arm B). The treatments were planned until best PSA response achievement or PSA progression. Toxicity was recorded according to NCIC criteria. Qol was assessed by self-filled questionnaires during the treatment. Results: Between 04/2003 and 09/2005, 95 pts (median age 69 years, range 48–86, median PSA 80 ng/ml, range 5–2,166 and measurable disease in 45) were randomized to arm A (49) or arm B (46). In arm A, pts received 321 cycles (median 6, range 0–28) with only 13 (4 %) delays = 7 days. In arm B, pts received 338 cycles (median 7, range 0–20) with only 16 (4.7%) delays. Grade 3–4 hematological toxicities consisted of neutropenia, 4% in arm A and 6% in B. One pt in arm B had febrile neutropenia and grade 3 diarrhea. Grade 3–4 non-hematologic toxicities were vomiting (1 pt in both arms), stomatitis (1 pt in arm A and 2 pts in B) and diarrhoea (1 pt in arm B). Two cases of stroke were reported in arm A. No treatment related death was recorded. Responses, in terms of PSA↓ >50% were: 40% in arm A and 75%in arm B with PSA normalization in 5% and 32% respectively. After a median follow-up of 17 months, 65 patients are died (31 in Arm A and 34 in Arm B). Progression free survival (biochemical) was 20 weeks in arm A and 30 in B. Conclusions: D-based regimens are active in HRPC with a manageable toxicity profile. From this preliminary data, DE combination appears promising, in terms of activity and tolerability so, front-to-front formal comparison in a phase III trial can be recommended. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- O. Caffo
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - T. Sava
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - E. Comploj
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - M. Giampaolo
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - F. Zustovich
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - R. Segati
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - C. Sacco
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - A. Perin
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - G. Pappagallo
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| | - F. Valduga
- Santa Chiara Hospital, Trento, Italy; Civil Hospital, Verona, Italy; Civil Hospital, Bolzano, Italy; Civil Hospital, Anagni, Italy; Civil Hospital, Padova, Italy; Civil Hospital, Feltre, Italy; Civil Hospital, Udine, Italy; Civil Hospital, Thiene, Italy; Civil Hospital, Noale, Italy
| |
Collapse
|
10
|
Sava T, Comploj E, Fariello G, Zustovich F, Segati R, Sacco C, Perin A, Mandarà M, Cetto G, Caffo O. Predictive value of PSA halving index (PSAHI) in patients (pts) with hormone refractory prostate cancer (HPRC): Results from a randomized phase II trial with docetaxel (D) ± estramustine phopshate (E). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15548 Background: D-based chemotherapy represents the standard treatment for HRPC pts. For several years PSA has been considered as a surrogate endpoint for studies involving pts with HRPC. The possibility of predicting a clinical advantage through the biochemical response rate is controversial. The PSAHI may represent a predictive parameter more than the simple PSA trend. We retrospectively evaluated the role of PSAHI in a consecutive series of patients affected by HRPC and treated in a randomized phase II trial with D±E. Methods: 95 pts affected by HRPC were randomized to D 70 mg/m2 IV d1 q3w (arm A: 49 pts) or D 70 mg/m2 IV d1 q3w + E 280 mg/TID PO starting 1 day prior to D, for 5 consecutive days (arm B: 46 pts). The treatment continued until best PSA response achievement or PSA progression. PSAHI was calculated comparing basal value (the day before first D administration) with those reached after every cycle at 21, 42, 63 and 84 days: each median value was then correlated across all pts. Correlations were made with response, time to progression (TTP) and overall survival (OS). Results: Responses, in terms of PSA? >50% were: 40% in arm A and 75%in arm B with PSA normalization in 5% and 32% respectively. After a median follow-up of 17 months, 65 patients are died (31 in Arm A and 34 in Arm B). Progression free survival (biochemical) was 20 weeks in arm A and 30 in B. Median PSAHI was 2.1 (0.8–8.8) and resulted significantly related to response and TTP: pts with PSAHI less than 1 and more than 1 had a median TTP of 14 and 34 weeks respectively. Between the 4 PSAHI analyzed (after 21, 42, 63 and 84 day), those at 42 and, particularly, 63 day resulted statistically related to response, TTP and OS. After 3 cycles, the PSA decline (63-PSAHI) was highly predicyive of OS which was 63, 72 and 90 weeks respectively (p=0.03), for pts with PSAHI of less than 1, between 1 and 3 and more than 3. Conclusions: PSAHI seems to be highly predictive of TTP and OS. 63-PSAHI seems to be a good surrogate marker of D response and may help in discriminating pts who need to be further treated with D and those who do not. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Sava
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - E. Comploj
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - G. Fariello
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - F. Zustovich
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - R. Segati
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - C. Sacco
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - A. Perin
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - M. Mandarà
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - G. Cetto
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| | - O. Caffo
- University of Verona, Verona, Italy; Ospedale Bolzano, Bolzano, Italy; Ospedale Trento, Trento, Italy; Ospedale Padova, Padova, Italy; Ospedale Rovereto, Rovereto, Italy; Ospedale Udine, Udine, Italy; Ospedale Thiene, Thiene, Italy
| |
Collapse
|
11
|
Mian C, Lodde M, Comploj E, Lusuardi L, Palermo S, Mian M, Maier K, Pycha A. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 2006; 59:984-7. [PMID: 16935973 PMCID: PMC1860484 DOI: 10.1136/jcp.2005.035394] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
AIM To establish independent prognostic factors on a chromosomal basis in superficial bladder cancer, using a multicolour fluorescence in situ hybridisation (FISH) probe mix. PATIENTS AND METHODS In 2002, voided urine from 75 consecutive patients (mean age 71.7, range 52-93) years under follow-up for superficial urothelial cancer was studied prospectively. The patients were observed for a mean (standard deviation (SD)) period of 39.3 (6.8) months (range 27-58) until July 2005. A multicolour FISH on liquid-based voided urinary cytology was carried out on all patients. Univariate analysis, using a log rank test, was used to determine the prognostic relevance of a low-risk pattern and a high-risk pattern. Progression-free survival time was calculated from the date of first diagnosis to first recurrence or progression according to the Kaplan-Meier product-limit method. RESULTS One patient was lost to follow-up. 27 of the 74 remaining (36.8%) patients showed recurrent disease. In 9 (33.3%) patients with a low-risk pattern disease recurred after a mean (SD) observation time of 29.7 (1.9) months (range 8.3-52.3, median 30.8 (12.4)). 18 (66.7%) patients with a high-risk pattern developed recurrence within a mean (SD) of 17.6 (2.0) months (range 4-38.8, median 16.7 (11.6)). The Kaplan-Meier curve for progression-free survival showed marked differences between the low-risk and the high-risk groups. CONCLUSION Patients with a high-risk chromosomal pattern have a markedly shorter disease-free survival time and higher progression rate than patients with a low-risk pattern. High-risk patients can therefore be treated more aggressively to prevent tumour spreading.
Collapse
Affiliation(s)
- C Mian
- Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Lusuardi L, Pycha A, Lodde M, Comploj E, Negri G, Edgarter-Vigl E, Palermo S, Mian C. MP-15.05. Urology 2006. [DOI: 10.1016/j.urology.2006.08.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Mian C, Lodde M, Comploj E, Marziani F, Chicchetti A, Spada A, Mian M, Pycha A, Lusuardi L. UP-02.29. Urology 2006. [DOI: 10.1016/j.urology.2006.08.771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
14
|
Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Valduga F, Frisinghelli M, Segati R, Sacco C, Perin A, Pappagallo G. A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4625] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4625 Background: D is presently considered a standard treatment for HRPC pts. E has shown a synergistic activity with D in vitro, however the role of D+E combination remains to be defined in the clinical practice. We attempted to evaluate the activity, in terms of PSA decline (PSA↓), the safety and quality of life (QoL) of D ± E in HRPC pts. Methods: eligibility criteria were: HRPC diagnosis, hormone-refractory advanced disease (PSA progression after at least two hormonal therapy), ECOG PS ≤ 2, adequate renal, hepatic and hematological functions. Pts were randomized to D 70 mg/m2 IV d1 q3w (arm A) or D 70 mg/m2 IV d1 q3w + E 280 mg/TID PO starting 1 day prior to D, for 5 consecutive days (arm B). The treatments were planned until best PSA response achievement or PSA progression. No anticoagulant prophylaxis was planned in ARM B pts. Qol was assessed by self-filled questionnaires during the treatment. Results: Between 04/2003 and 09/2005, 95 pts (median age 69 years, range 48–86, median PSA 80 ng/ml, range 5–2166 and measurable disease in 45) were randomized to arm A (49) or arm B (46). To date, 9 pts and 6 pts are still on treatment in arm A and B respectively. In arm A, pts received 257 cycles (median 5, range 1–14) with only 10 (3.9%) delays ≥ 7 days. In arm B, pts received 317 cycles (median 7, range 0–20) with only 15 (4.7%) delays. Median follow-up was 19.5 months. Grade 3–4 hematological toxicities consisted of neutropenia, 4% in arm A and 8% in B, anemia, 0% and 2% respectively and 1 pt with febrile neutropenia and grade 3 diarrhea (Arm B). Grade 3−4 non-hematologic toxicities were vomiting (1 pt) in arm A, stomatitis (2 pts) and vomiting (1 pt) in arm B. Two cases of stroke were reported in arm A. Responses, in terms of PSA↓ >50% were: 43% in arm A and 70% in arm B with PSA normalization in 8% and 38% respectively. Progression free survival (biochemical) was 20 weeks in arm A and 31 in B. Analysis concerning QoL outcomes is planned at the treatment completion of all pts. Conclusions: D-based regimens are active in HRPC with a low toxicity profile. From this preliminary data, DE combination appears promising, in terms of activity and tolerability so, front-to-front formal comparison in a phase III trial can be recommended. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- O. Caffo
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - T. Sava
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - E. Comploj
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - A. Fariello
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - F. Zustovich
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - F. Valduga
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - M. Frisinghelli
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - R. Segati
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - C. Sacco
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - A. Perin
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| | - G. Pappagallo
- Santa Chiara Hospital, Trento, Italy; Medical Oncology Department, Verona, Italy; Urology Department, Bolzano, Italy; Medical Oncology Department, Sora, Italy; Medical Oncology Department, Padova, Italy; Medical Oncology Department, Trento, Italy; Medical Oncology Department, Feltre, Italy; Medical Oncology Department, Udine, Italy; Medical Oncology Department, Thiene, Italy; Medical Oncology Department, Noale, Italy
| |
Collapse
|
15
|
Pycha A, Lodde M, Comploj E, Lusuardi L, Palermo S, Mian M, Maier K, Mian C. MULTICOLOUR-FISH FOR THE RISK-STRATIFICATION OF SUPERFICIAL BLADDER CANCER. ACTA ACUST UNITED AC 2006. [DOI: 10.1016/s1569-9056(06)60930-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Mian C, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Lusuardi L, Palermo S, Marberger M, Pycha A. Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma. Cytopathology 2004; 14:338-42. [PMID: 14632732 DOI: 10.1046/j.0956-5507.2003.00094.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The aim of the study was to assess the value of liquid-based urinary cytology as a tool to perform uCyt+ and Multicolour-FISH in patients under follow-up after urothelial cancer. Therefore, standard cytology was compared to liquid-based cytology with the addition of the uCyt+ test, which traces the three monoclonal antibodies M344, LDQ10 and 19A211 in exfoliated urothelial cells; and Multicolour-FISH (including centromere-specific probes for chromosomes 3, 7, 17 and a locus-specific probe for 9p21/p16) performed on thin-layer specimens. UCyt+ showed an overall sensitivity of 86.2% and cytology of 45.0%. Overall sensitivity of both the tests combined was 90%. Sensitivity of Multicolour-FISH was 96.4%. All conventional cytology diagnoses were confirmed by liquid-based cytology. Liquid-based cytology is a valid tool for the performance of adjunctive analyses, such as uCyt+ and Multicolour-FISH, on residual cellular material.
Collapse
Affiliation(s)
- C Mian
- Department of Pathology, General Hospital of Bolzano, Bolzano, Austria.
| | | | | | | | | | | | | | | | | |
Collapse
|